While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

“Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

drugmaker Novo Nordisk said Tuesday. A Phase 3 clinical trial found that injections of the semaglutide medication once weekly ...

The list of 15 medicines includes blockbuster drugs from Novo Nordisk ... of Novo’s entire semaglutide franchise—Type 2 diabetes injection Ozempic and oral tablet Rybelsus, plus weight ...

Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus oral tablets for type II diabetes (T2D) and Wegovy injections for weight management. Any price reduction ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...